Skip to content

Preferred Stock at other companies

Incyte logo
IncyteINCY
$0
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$0
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$0
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$0
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$0
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$0

Other financials

Income statement

See full
Revenue$15.0K-97.8%
Operating income-$84.4M-34.6%
Net income-$78.7M-46.3%
EPS (diluted)-$1.18-45.7%

Balance sheet

See full
Cash & equivalents$35.7M+109%
Total debt$1.9M-44.3%
Total equity$456.2M-35.1%
Total assets$511.3M-30.9%

Cash flow

See full
Operating cash flow-$65.6M-20.6%
CapEx$1.6M+518%
Free cash flow-$67.2M-23.0%

Valuation

See full
Market cap$2.65B+75.2%

Profitability

See full
Operating margin-35,688.5%-39,114pp
Net margin-32,753.6%-35,519pp
FCF margin-26,125.8%-28,907pp

Returns & leverage

See full
Return on equity-48.9%-498pp
Debt / equity0.0×
Current ratio8.9×-12.7×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Celldex Therapeutics’s 10-Q, filed August 8, 2023, on SEC EDGAR. View the filing →

Questions, answered.

What is Celldex Therapeutics's preferred stock?
Celldex Therapeutics (CLDX) reported preferred stock of $0 in Q4 2022.
What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.